Richard Croarkin - Aerie Pharmaceuticals Independent Director
| AERIDelisted Stock | USD 15.25 0.01 0.07% |
Director
Mr. Richard J. Croarkin is Independent Director of Aerie Pharmaceuticals, Inc. Mr. Croarkin has served as a member of our Board since May 2015. Mr. Croarkin previously was Chief Financial Officer of Nestle Health Science, a division of Nestle focused on medicalized nutrition solutions for chronic medical conditions, from December 2010 to February 2013. From 2007 to 2010, Mr. Croarkin was Senior Vice President, Chief Financial Officer, and Corporationrationrate Strategy Officer at Alcon, which had annual sales of 7.1 billion and was the worlds leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis for 50 billion. In 2008 and 2009, Mr. Croarkin also served as a director on the supervisory board of the German publiclytraded company, WaveLight A.G., which manufactures and globally markets laser and diagnostic systems for refractive eye surgery. Previously, Mr. Croarkin was Executive Vice President and Chief Financial Officer of Nestle Waters North America, overseeing the finances of a business unit that grew to 4.4 billion in sales. Before joining Nestle, Mr. Croarkin worked for Pepsico Incorporated, where he served in a number of senior financial positions around the world, including as Chief Financial Officer of Pepsi Latin America and Pepsi Canada. Mr. Croarkin started his career with AMAX, Inc., where he worked in treasury, corporate development and planning. Mr. Croarkin currently serves as a member of the board of directors of Clearside Biomedical, a company advancing eye disease therapies by delivering drugs to the suprachoroidal space via a proprietary microinjector. He also serves on occasion as a panelist on the NASDAQ Listing Qualifications Panel. In 2018, Mr. Croarkin was elected to the Board of Waveny LifeCare Network, Inc., a notforprofit nursing home and healthcare provider for Southwestern Connecticuts senior population since 2015.
| Age | 63 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 919 237-5300 |
| Web | www.aeriepharma.com |
Aerie Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0459) % which means that it has lost $0.0459 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.5501) %, meaning that it created substantial loss on money invested by shareholders. Aerie Pharmaceuticals' management efficiency ratios could be used to measure how well Aerie Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 234.53 M in liabilities with Debt to Equity (D/E) ratio of 9.41, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aerie Pharmaceuticals has a current ratio of 2.55, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Aerie Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aerie Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aerie Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aerie to invest in growth at high rates of return. When we think about Aerie Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Maples | Q2 Holdings | 75 | |
| CPA JD | Willamette Valley Vineyards | 77 | |
| Matthew Behrent | Asure Software | 46 | |
| Christopher Sarles | Willamette Valley Vineyards | 49 | |
| Michael Brown | Q2 Holdings | 44 | |
| Carl Schaper | Q2 Holdings | 66 | |
| Heather Westing | Willamette Valley Vineyards | N/A | |
| Brad Burrows | Asure Software | N/A | |
| Stan Turel | Willamette Valley Vineyards | 65 | |
| Stanley Turel | Willamette Valley Vineyards | 66 | |
| Sean Cary | Willamette Valley Vineyards | 40 | |
| James Ellis | Willamette Valley Vineyards | 69 | |
| Charles Doyle | Q2 Holdings | 84 | |
| Randall Waterfield | Asure Software | 43 | |
| Adrian Pertierra | Asure Software | 45 | |
| Craig Smith | Willamette Valley Vineyards | 67 | |
| Daniel Gill | Asure Software | 53 | |
| Charles Lathrop | Asure Software | 61 | |
| Shay David | Kaltura | 51 | |
| Jeffrey Diehl | Q2 Holdings | 50 | |
| Jonathan Ricci | Willamette Valley Vineyards | N/A | |
Management Performance
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 |
Aerie Pharmaceuticals Leadership Team
Elected by the shareholders, the Aerie Pharmaceuticals' board of directors comprises two types of representatives: Aerie Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aerie. The board's role is to monitor Aerie Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aerie Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aerie Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wanda Francies, Head HR | ||
| Vicente Anido, Chairman and CEO | ||
| Julie McHugh, Independent Director | ||
| Peter Lang, Chief Officer | ||
| Marvin Garrett, Head Assurance | ||
| Casey Kopczynski, Co-Founder and Chief Scientific Officer | ||
| Benjamin McGraw, Independent Director | ||
| Craig Skenes, Head Devel | ||
| Thomas Mitro, Pres and COO | ||
| Eric Carlson, Vice President - Research & Development | ||
| Raj Kannan, Principal CEO | ||
| Jeffrey CPA, VP Officer | ||
| Deanne Melloy, Vice President - Marketing | ||
| Michelle Senchyna, Head Operations | ||
| David Gryska, Independent Director | ||
| Murray Goldberg, Board Member | ||
| Richard Lewis, Chief Medical Officer | ||
| John LaRocca, General Counsel | ||
| Richard Rubino, CFO | ||
| John Esq, G Sec | ||
| Anand Mehra, Director | ||
| Gerald Cagle, Director | ||
| Richard Croarkin, Independent Director | ||
| Michael Toit, Independent Director | ||
| Tori Arens, Vice President - Drug Product Manufacturing | ||
| Carolyn McAuliffe, Director Communications | ||
| Geoffrey Duyk, Director |
Aerie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aerie Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 | |||
| Profit Margin | (0.17) % | |||
| Operating Margin | (0.12) % | |||
| Current Valuation | 918.14 M | |||
| Shares Outstanding | 49.42 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Number Of Shares Shorted | 1.52 M | |||
| Price To Earning | (19.00) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aerie Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aerie Pharmaceuticals' short interest history, or implied volatility extrapolated from Aerie Pharmaceuticals options trading.
Pair Trading with Aerie Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aerie Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aerie Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Aerie Stock
| 0.48 | PME | Pingtan Marine Enterprise | PairCorr |
| 0.41 | PFE | Pfizer Inc Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Aerie Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aerie Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aerie Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aerie Pharmaceuticals to buy it.
The correlation of Aerie Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aerie Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aerie Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aerie Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Aerie Stock
If you are still planning to invest in Aerie Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aerie Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |